12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MEK162: Phase II started

Novartis began an open-label, international Phase II trial to evaluate twice-daily 45 mg oral MEK162 in about 54 patients with BRAF V600E and neuroblastoma Ras viral (v-Ras) oncogene (NRAS)...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >